The Journal of Pediatrics
Volume 153, Issue 4 , Pages 491-497 , October 2008

Risk Factors for Cardiovascular Disease in Children Infected with Human Immunodeficiency Virus-1

  • Tracie L. Miller, MD

      Affiliations

    • Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL
    • Corresponding Author InformationReprint requests: Tracie L. Miller, MD, Division of Pediatric Clinical Research, Department of Pediatrics (D820), Miller School of Medicine at the University of Miami, Batchelor Children's Research Institute, PO Box 016820, Miami, FL 33101
    • ,
  • E. John Orav, PhD

      Affiliations

    • Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA
    • ,
  • Steven E. Lipshultz, MD

      Affiliations

    • Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL
    • ,
  • Kristopher L. Arheart, EdD

      Affiliations

    • Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL
    • ,
  • Christopher Duggan, MD, MPH

      Affiliations

    • Division of Gastroenterology and Nutrition, Children's Hospital, Harvard Medical School, Boston, MA
    • ,
  • Geoffrey A. Weinberg, MD

      Affiliations

    • Division of Infectious Disease, Golisano Children's Hospital at Strong, University of Rochester School of Medicine, Rochester, NY
    • ,
  • Lori Bechard, RD, MS

      Affiliations

    • Division of Gastroenterology and Nutrition, Children's Hospital, Harvard Medical School, Boston, MA
    • ,
  • Lauren Furuta, RD, MS

      Affiliations

    • Division of Gastroenterology and Nutrition, Children's Hospital, Harvard Medical School, Boston, MA
    • ,
  • Jeanne Nicchitta, RD, MS

      Affiliations

    • Division of Gastroenterology, Golisano Children's Hospital at Strong, University of Rochester School of Medicine, Rochester, NY
    • ,
  • Sherwood L. Gorbach, MD

      Affiliations

    • Department of Family Medicine and Community Health, Tufts University School of Medicine, Boston, MA
    • Department of Medicine, Tufts-New England Medical Center, Boston, MA
    • ,
  • Abby Shevitz, MD

      Affiliations

    • Department of Family Medicine and Community Health, Tufts University School of Medicine, Boston, MA
    • Dr. Abby Shevitz is deceased.

Received 6 November 2007 ,Revised 24 January 2008 ,Accepted 3 April 2008.

References 

  1. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism?. JAMA. 1998;280:72–77
  2. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006;185:1–11
  3. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor–associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 1998;351:1881–1883
  4. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus–infected children. J Clin Endocrinol Metab. 2005;90:168–174
  5. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443–1451
  6. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123–2128
  7. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17(Suppl 1):S130–S140
  8. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27:30–34
  9. Fallo AA, Sanchez A, Gaete L, Torrado L, Trifone L, Tonieti M, et al. Metabolic complications of HIV therapy in children from Argentina. Abstract 885. Presented at the IDSA 45th Annual Meeting, October 4-7, 2007.
  10. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003
  11. Hadigan C, Meigs JB, Corcoran C. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130–139
  12. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45:1074–1081
  13. Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, Luder E, et al. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective P2C2 Human Immunodeficiency Virus Multicenter Study. Pediatrics. 2001;108:1287–1296
  14. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1–infected children. Pediatrics. 2001;107:e77
  15. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus–infected children receiving long-term, protease inhibitor–containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114:e235–e242
  16. Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor–treated and –naive HIV-infected children. AIDS. 2003;17:1319–1327
  17. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency syndrome in children less than 13 years of age. MMWR Recom Rep. 1994;43(RR-12):1–10
  18. Roberts SLW. Nutritional Assessment Manual. Iowa City, IA: University of Iowa Hospital and Clinics; 1987;
  19. United States Department of Health, Education, and Welfare. Ten-State Nutrition Survey in the United States 1968-1970. Atlanta, GA: Centers for Disease Control; 1972;
  20. Kuczmarski RJ, Ogden CL, Guo SS, Mei Z, Guo S, Wei R, et al. CDC growth charts: United States. Adv Data. 2000;314:1–27
  21. National Health and Nutrition Examination Survey III. Body measurements (anthropometry). http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/anthro.pdfAccessed April 15, 2008
  22. Treuth MS, Hunter GR, Kekes-Szabo T. Estimating intra-abdominal adipose tissue in women by dual-energy X-ray absorptiometry. Am J Clin Nutr. 1995;62:527–532
  23. Miller TL, Evans SJ, Orav EJ, Morris V, McIntosh K, Winter HS. Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr. 1993;57:588–592
  24. McKinney RE, Robertson JW. Effect of human immunodeficiency virus infection on the growth of young children (Duke Pediatric AIDS Clinical Trials Unit). J Pediatr. 1993;123:579–582
  25. Miller TL, Orav EJ, Martin SR, Cooper ER, McIntosh K, Winter HS. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology. 1991;100:1296–1302
  26. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27–31
  27. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation. 1999;100:700–705
  28. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY Study. Pediatr Pathol Mol Med. 2002;21:213–237
  29. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med. 1998;338:1650–1656
  30. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab. 2003;88:2534–2540
  31. Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol. 2000;20:1932–1938
  32. Ludescher B, Najib A, Baar S, Machann J, Thamer C, Schick F, et al. Gender specific correlations of adrenal gland size and body fat distribution: a whole-body MRI study. Horm Metab Res. 2007;39:515–518
  33. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, et al. Pediatric AIDS Clinical Trials Group Study 219C Team Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr. 2005;38:480–487
  34. Bonnet E, Ruidavets JB, Tuech J, Ferrières J, Collet X, Fauvel J, et al. Apoprotein c-III– and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001;86:296–302
  35. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225–235
  36. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266–1273
  37. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275–e281
  38. Miller TL. A hospital-based exercise program to improve body composition, strength, and abdominal adiposity in 2 HIV-infected children. AIDS Reader. 2007;17:450–455

 Supported by National Institutes of Health grants P01 DK45734, M01 RR00054, M01 RR00044, and M01 RR02172. The authors have no potential, perceived, or real conflicts of interest to declare.

PII: S0022-3476(08)00284-9

doi: 10.1016/j.jpeds.2008.04.016

The Journal of Pediatrics
Volume 153, Issue 4 , Pages 491-497 , October 2008

Article Tools